Cannabis Stocks: Aurora Trades Below Both Takeover Offers as Tilray Slips Ahead of Wednesday’s Annual Meeting and Cronos Cites 73% Organic Growth

Cannabis plants and Canadian cannabis industry investment gemini generated image rf1nqfrf1nqfrf1n

Table of Contents

  • Market Context
  • What Happened
  • Why It Matters
  • Sector Breakdown
  • Risks to Watch
  • What to Watch Next
  • Final Outlook

Market Context

Canadian cannabis companies have spent years as a story about consolidation rather than growth. Oversupply, price competition and thin margins pushed the sector to shrink, and many of the biggest names now trade at fractions of their former value. Tilray, for instance, is down more than 70% this year and sits near the bottom of a 52-week range that ran from about US$2.33 to US$15.70.

That backdrop explains why takeover activity has become the sector’s most closely watched theme. Two bidders are now competing for Aurora Cannabis, an unusual situation in an industry where buyers have been scarce. U.S. policy adds a second layer: in April, the Justice Department moved FDA-approved and state-licensed marijuana from Schedule I to Schedule III, but the scope was narrow, and Canadian producers do not benefit directly.

Monday’s trading showed how sensitive the group remains to both stories.

What Happened

Cannabis stocks were broadly lower. One market summary found that 24 of 35 cannabis-linked stocks traded below their previous close. Aurora Cannabis traded in a range of roughly US$4.6 to US$4.9, below both takeover offers, with reported moves ranging from about 1% to nearly 7% lower depending on the time of the quote. Organigram agreed on November 3 to buy Aurora for C$7.80 a share, while Curaleaf’s rival offer, reported at 0.4013 Curaleaf shares plus US$1 in cash per Aurora share, has cleared competition approvals in Germany and Canada and is due to expire on December 4. Aurora’s board has urged shareholders to reject the Curaleaf offer in favour of the Organigram deal.

Tilray fell about 2.4% to 3.7% to roughly US$2.43 ahead of its annual meeting on Wednesday. Canopy Growth slipped about 2.2% to about US$0.56, SNDL about 1.4% to US$1.37 and Curaleaf about 2.6% to US$7.85. Cronos Group traded near US$3.3, after reporting third-quarter net revenue up 73% on an organic, constant-currency basis, with record results in Canada and Israel. On the policy side, the U.S. Senate Appropriations Committee proposed on Friday to extend protections for state medical cannabis programs without adopting a House provision against rescheduling. The S&P/TSX Composite fell 1.1% to about 35,713.

Also Read: Dividend paying stocks Canada

Why It Matters

Takeover math is the sector’s clearest signal

Aurora trading below both bids suggests investors see uncertainty in completing either deal, particularly because Curaleaf’s offer is part-paid in shares whose value moves daily. For shareholders, the choice is between a cash-heavy Canadian deal and a larger U.S.-linked transaction.

Policy relief is real but narrow

Rescheduling helps U.S. state-licensed operators by ending certain tax penalties, but Canadian producers do not benefit directly. Legalization at the federal level in the U.S. remains uncertain and could take years.

Sector Breakdown

Larger Canadian producers such as Canopy Growth, Tilray and Aurora are working through different strategies, from U.S. expansion and beverage and wellness businesses to domestic consolidation. Tilray’s emphasis on the U.S. market may explain why it has not entered the Aurora bidding.

Cronos stands out for its balance sheet and growth, with organic revenue up 73% and a reduced share count, though it is still a small business. Curaleaf, a large U.S. multi-state operator listed in Toronto, represents the U.S. side of the sector and carries debt and tax exposure that rescheduling could help. SNDL and other diversified Canadian companies add retail and investment exposure. No Canadian cannabis earnings beyond Cronos were identified in the data reviewed.

Risks to Watch

Deal risk is first: either Aurora transaction could fail, change or be topped, and the Curaleaf offer expires December 4. Regulatory risk in the United States remains substantial, since a House provision against rescheduling could still resurface. Liquidity and valuation risks are significant in a sector where many shares trade near or below US$1.

Earnings risk matters because competition and pricing pressure continue to squeeze margins. Dilution, financing and interest-rate risk apply to companies with debt, and a weak broad market, as on Monday, can pull speculative sectors lower.

What to Watch Next

Investors should watch Tilray’s annual meeting on Wednesday, any amended terms or shareholder votes on the Aurora transactions, and the December 4 deadline for the Curaleaf offer. Congressional action on appropriations and rescheduling, along with further third-quarter results from cannabis companies, will matter. Canadian excise and pricing developments could also affect domestic producers.

Final Outlook

Cannabis stocks remain a speculative, event-driven corner of the market. The Aurora contest offers a concrete catalyst, but Monday’s weakness in most names shows that sentiment is fragile and that deal premiums are not guaranteed. For investors, balance-sheet strength and clarity on deal terms may matter more than headlines about U.S. reform.

Verdict: Watchlist candidate, not a broad buy signal. Monitor the Aurora offers and the December 4 deadline.

Sign Up For our Newsletters to get latest updates

Leave a Reply

Your email address will not be published. Required fields are marked *

×